



PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 58569

Title: Effects of transjugular intrahepatic portosystemic shunt using the Viatorr stent on hepatic reserve function in patients with cirrhosis

Reviewer’s code: 01221925

Position: Editorial Board

Academic degree: AGAF, FACS, FICS, MD, PhD

Professional title: Associate Professor

Reviewer’s Country/Territory: Greece

Author’s Country/Territory: China

Manuscript submission date: 2020-07-28

Reviewer chosen by: Ya-Juan Ma

Reviewer accepted review: 2020-11-04 07:08

Reviewer performed review: 2020-11-07 14:45

Review time: 3 Days and 7 Hours

| | |
|---------------------------------|---|
| Scientific quality | <input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish |
| Language quality | <input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| Conclusion | <input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection |
| Re-review | <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No |
| Peer-reviewer statements | Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

This is an interesting paper evaluating the effects of transjugular intrahepatic portosystemic shunt using the Viatorr stent on hepatic reserve function in patients with cirrhosis. Could the authors please respond to the following questions/comments: 1) The authors mention 100% success rate, but patients with stent dysfunction are excluded from the study. What were the reasons for stent dysfunction and why were these patients excluded? 2) In the results there is a sentence "There were 50 cases of hepatic encephalopathy at 24 months, with an A/B/C group ratio of 6%/8%." Can the authors clarify the incidence for each of the groups? 3) For the patients that died from liver failure, were any other types of treatment considered, ie liver transplantation? 4) How do the authors explain the fact that group A had less encephalopathy but worse patient outcomes? Is it simply a matter of the disease etiology? How was the disease etiology managed in these patients, apart from the TIPS?